Conservative Management of Uterine Adenomyosis: Medical vs. Surgical Approach
Open accessThe DOI matches its Crossref record; 102 of the 103 references it cites were found in a registry or an index.
Abstract
Uterine adenomyosis is a commonly encountered estrogen-dependent disease in reproductive-age women, causing heavy menstrual bleeding, intense pelvic pain, and infertility. Although adenomyosis was previously considered a disease of multiparous women, it is becoming increasingly evident that it also affects younger nulliparous women and may compromise their fertility potential. It is clear that hysterectomy, the standard approach to definitively manage the disease, is not an option for patients wishing to preserve their fertility, so there is an urgent need to develop novel conservative strategies. We searched the current literature for available methods for conservative management of adenomyosis, including both pharmacological and surgical approaches. There is no existing drug that can cure adenomyosis at present, but some off-label treatment options may be used to tackle disease symptoms and improve fertility outcomes. Adenomyosis in patients wishing to conceive can be ‘treated’ by conservative surgery, though these procedures require highly experienced surgeons and pose a considerable risk of uterine rupture during subsequent pregnancies. While currently available options for conservative management of adenomyosis do have some capacity for alleviating symptoms and enhancing patient fertility perspectives, more effective new options are needed, with gonadotropin-releasing hormone antagonists showing encouraging results in preliminary studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Schematic representation of the triple-flap method applied to the anterior and posterior uterine wall. The approach involves complete extraction of the uterine adenomyosis (A–C), followed by reconstruction of the uterine cavity (D–F). An endometrial uterine muscle flap is created by metroplasty and uterine muscle located on the serosal side is used to fill the large uterine wall muscle defect (E,F) (reprinted with permission from [95]).](https://figures.cochat.ai/paper-figures/1fab60a6d4ed43bf9942d9a5f3100fd1/conservative-management-of-uterine-adenomyosis-medical-vs-surgical-approach-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“adenomyosis (AD) and certain subtypes of endometriosis, such as deep endometriosis (DE), do not respond to hormonal treatment as well as ovarian endometrioma (OE) (Stratopoulou et al., 2021; Vannuccini et al., 2022)”
From Progressively diminished estrogen signaling concordant with increased fibrosis in ectopic endometrium (2025) · cites this paper as Stratopoulou et al., 2021
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nisolle, M., & Donnez, J. (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)00191-x · Cited by 1,279 · cited 1×
“Impaired stromal decidualization may constitute another reason, given the frequently encountered resistance to progesterone in adenomyosis patients, a hormone playing a pivotal role in the transition of endometrium to its decidualized state [1,15,82,83].”
BackgroundSelf-citationWhat we know about primary dysmenorrhea today: a critical review
Iacovides, S., Avidon, I., & Baker, F. C. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmv039 · Cited by 1,022 · cited 2×
“NSAIDs block cyclooxygenase, suppress prostaglandin, and alleviate uterine hypercontractility, so they relieve pain without treating potential underlying causes, as in case of adenomyosis and endometriosis [8].”
BackgroundUlipristal Acetate versus Placebo for Fibroid Treatment before Surgery
Donnez, J., Tatarchuk, T. F., Bouchard, P., Puscasiu, L., Zakharenko, N. F., Ivanova, T., Ugocsai, G., Mara, M., Jilla, M. P., Bestel, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1103182 · Cited by 680
Self-citationNonsteroidal anti-inflammatory drugs for dysmenorrhoea
Marjoribanks, J., Ayeleke, R. O., Farquhar, C., & Proctor, M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001751.pub3 · Cited by 562
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
Taylor, H. S., Giudice, L. C., Lessey, B. A., Abrao, M. S., Kotarski, J., Archer, D. F., Diamond, M. P., Surrey, E., Johnson, N. P., Watts, N. B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700089 · Cited by 511
The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices
Rivera, R., Yacobson, I., & Grimes, D. (1999) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(99)70120-1 · Cited by 400 · cited 1×
“Combined oral contraceptives (COCs) act by inhibiting follicle-stimulating hormone (FSH) and luteinizing hormone (LH), subsequently blocking follicle development and endometrial proliferation, which is why they were proposed to treat adenomyosis-related symptoms [10].”
BackgroundHorton, J., Sterrenburg, M., Lane, S., Maheshwari, A., Li, T. C., & Cheong, Y. (2019) · Human Reproduction Update · doi:10.1093/humupd/dmz012 · Cited by 376 · cited 1×
“Adenomyosis has been repeatedly associated with both poor in vitro fertilization (IVF) outcomes and pregnancy complications [79,80].”
BackgroundKitawaki, J., Noguchi, T., Amatsu, T., Maeda, K., Tsukamoto, K., Yamamoto, T., Fushiki, S., Osawa, Y., & Honjo, H. (1997) · Biology of Reproduction · doi:10.1095/biolreprod57.3.514 · Cited by 305
Four subtypes of adenomyosis assessed by magnetic resonance imaging and their specification
Kishi, Y., Suginami, H., Kuramori, R., Yabuta, M., Suginami, R., & Taniguchi, F. (2012) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2012.06.027 · Cited by 301 · cited 1×
“[20]) may be more prone to developing serious menorrhagia upon dienogest administration than other disease subtypes [21].”
BackgroundGnRH and GnRH receptors in the pathophysiology of the human female reproductive system
Maggi, R., Cariboni, A. M., Marelli, M. M., Moretti, R. M., Andrè, V., Marzagalli, M., & Limonta, P. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmv059 · Cited by 269 · cited 2×
“These molecules antagonize GnRH binding to its receptors, leading to dose-dependent suppression of FSH and LH and a subsequent decline in ovarian steroids [15,41].”
BackgroundEffects of adenomyosis on in vitro fertilization treatment outcomes: a meta-analysis
Younes, G., & Tulandi, T. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.06.025 · Cited by 268 · cited 1×
“Adenomyosis has been repeatedly associated with both poor in vitro fertilization (IVF) outcomes and pregnancy complications [79,80].”
BackgroundEstrogen-progestins and progestins for the management of endometriosis
Vercellini, P., Buggio, L., Berlanda, N., Barbara, G., Somigliana, E., & Bosari, S. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.10.022 · Cited by 243 · cited 2×
“As in endometriosis, progesterone receptors in adenomyotic uteri are either diminished or inactive, thus inhibiting the action of both local and synthetic progesterone forms [1,15,31,32].”
BackgroundRole of medical therapy in the management of uterine adenomyosis
Vannuccini, S., Luisi, S., Tosti, C., Sorbi, F., & Petraglia, F. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.01.013 · Cited by 231 · cited 4×
“Our search revealed that there is as yet no drug specifically registered to treat adenomyosis, but various off-label treatments have emerged over the years, some of them with acceptable efficacy [6].”
BackgroundInfluentialUterine adenomyosis and adenomyoma: the surgical approach
Osada, H. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.01.032 · Cited by 219 · cited 9×
“is technique, therefore, repairs the uterine wall defect using normal uterine muscle and, according to Osada, is effectiv for both diffuse and nodular adenomyosis, p tentially helping to prevent ut rine rupture [95].”
BackgroundMethodInfluentialNonsteroidal anti-inflammatory drugs for heavy menstrual bleeding
Lethaby, A., Augood, C., & Duckitt, K. (1998) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000400 · Cited by 206
Sheng, J., Zhang, W. Y., Zhang, J. P., & Lu, D. (2009) · Contraception · doi:10.1016/j.contraception.2008.11.004 · Cited by 204 · cited 1×
“On the contrary, another trial demonstrated more long-term effects of the LNG-IUD against adenomyosis symptoms, as both dysmenorrhea and uterine volume remained significantly reduced after 3 years of follow-up of 94 enrolled patients [29].”
Adenomyosis incidence, prevalence and treatment: United States population-based study 2006–2015
Yu, O., Schulze-Rath, R., Grafton, J., Hansen, K., Scholes, D., & Reed, S. D. (2020) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2020.01.016 · Cited by 200
Liu, X., Shen, M., Qi, Q., Zhang, H., & Guo, S.-W. (2016) · Human Reproduction · doi:10.1093/humrep/dew018 · Cited by 190 · cited 1×
“One mouse model-based study suggested the potential utility of ozagrel, an antiplatelet drug, for treatment of adenomyosis, after observing enhanced platelet aggregation in mouse and human lesions [71,72].”
BackgroundDonnez, J., & Dolmans, M.-M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10051085 · Cited by 182 · cited 7×
“Impaired stromal decidualization may constitute another reason, given the frequently encountered resistance to progesterone in adenomyosis patients, a hormone playing a pivotal role in the transition of endometrium to its decidualized state [1,15,82,83].”
BackgroundInfluentialSelf-citationOsada, H., Silber, S., Kakinuma, T., Nagaishi, M., Kato, K., & Kato, O. (2011) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2010.09.014 · Cited by 176 · cited 1×
“With a view to future pregnancy, the triple-flap method has been proposed as an innovative and safer technique for removal of adenomyosis and reconstruction of the uterine wall [95,97].”
MethodNonsteroidal anti-inflammatory drugs for primary dysmenorrhoea
Marjoribanks, J., Proctor, M., Farquhar, C., Sangkomkamhang, U. S., & Derks, R. S. (2003) · The Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001751 · Cited by 167 · cited 2×
“ith a view to future pregnancy, the triple-flap method has b en proposed as an innovative f r technique for emoval of adenomyosis and reconstruction of the uterine wall [95, 7].”
BackgroundMethodNiu, Z., Chen, Q., Sun, Y., & Feng, Y. (2013) · Gynecological Endocrinology · doi:10.3109/09513590.2013.824960 · Cited by 166 · cited 2×
“reported a significant improvement in rates of clinical pregnancy, successful implantation, and ongoing pregnancy in 339 infertile patients with adenomyosis undergoing treatment with GnRH agonist prior to frozen embryo transfer [48].”
BackgroundLarge, M. J., & DeMayo, F. J. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.07.027 · Cited by 162 · cited 1×
“Impaired stromal decidualization may constitute another reason, given the frequently encountered resistance to progesterone in adenomyosis patients, a hormone playing a pivotal role in the transition of endometrium to its decidualized state [1,15,82,83].”
BackgroundBragheto, A. M. D. S., Caserta, N. M. G., Bahamondes, L. G., & Petta, C. A. (2007) · Contraception · doi:10.1016/j.contraception.2007.05.091 · Cited by 146
Tremellen, K. P., & Russell, P. (2011) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2011.12.001 · Cited by 145 · cited 1×
“On the other hand, the chronic inflammatory endometrial environment may be the underlying cause of adenomyosis-related infertility, as it is hostile to embryos [84].”
BackgroundClinical effects of the levonorgestrel-releasing intrauterine device in patients with adenomyosis
Cho, S., Nam, A., Kim, H., Chay, D. B., Park, K., Cho, D. J., Park, Y., & Lee, B. S. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2007.10.798 · Cited by 143 · cited 1×
“One clinical trial involving 47 patients reported pain relief from the sixth week after insertion, and a significant decrease in mean uterine volume by month 12 [28].”
BackgroundÖzdeğirmenci, Ö., Kayıkçıoğlu, F., Akgül, M. A., Kaplan, M., Karçaaltıncaba, M., Haberal, A., & Akyol, M. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.10.009 · Cited by 139
Park, C. W., Choi, M. H., Yang, K. M., & Song, I. O. (2016) · Clinical and Experimental Reproductive Medicine · doi:10.5653/cerm.2016.43.3.169 · Cited by 135 · cited 1×
“A more recent study, however, failed to identify a significant difference in clinical pregnancy rates between 241 treated and untreated infertile adenomyosis patients in this category [89].”
ResultDiamond, M. P., Carr, B. R., Dmowski, W. P., Koltun, W. D., O'Brien, C. F., Jiang, P. X., Burke, J., Jimenez, R., Garner, E. I. O., & Chwalisż, K. (2013) · Reproductive Sciences · doi:10.1177/1933719113497292 · Cited by 127
Donnez, J., Taylor, H. S., Taylor, R. N., Akin, M. D., Tatarchuk, T. F., Wilk, K., Gotteland, J.-P., Lecomte, V., & Bestel, E. (2020) · Fertility and Sterility · doi:10.1016/j.fertnstert.2020.02.114 · Cited by 124
Self-citationUterine Artery Embolization for the Treatment of Adenomyosis: A Systematic Review and Meta-Analysis
de Bruijn, A. M., Smink, M., Lohle, P. N. M., Huirne, J. A. F., Twisk, J. W. R., Wong, C. F. C., Schoonmade, L. J., & Hehenkamp, W. J. K. (2017) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2017.07.034 · Cited by 123 · cited 3×
“Indeed, as clarified by the same authors, limitations are numerous and include the retrospective evaluation of data, small sample size, and vague description of methodology [101].”
BackgroundMethodOsuga, Y., Fujimoto-Okabe, H., & Hagino, A. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.07.021 · Cited by 119 · cited 1×
“A shorter course of dienogest therapy (16 weeks) was still associated with abnormal menstrual bleeding, but not severe anemia in most patients [19].”
BackgroundProgesterone Receptor Status Predicts Response to Progestin Therapy in Endometriosis
Flores, V. A., Vanhie, A., Dang, T., & Taylor, H. S. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01227 · Cited by 118 · cited 2×
“As in endometriosis, progesterone receptors in adenomyotic uteri are either diminished or inactive, thus inhibiting the action of both local and synthetic progesterone forms [1,15,31,32].”
BackgroundLong-term management of adenomyosis with a gonadotropin-releasing hormone agonist: a case report
Nelson, J. R., & Corson, S. L. (1993) · Fertility and Sterility · doi:10.1016/s0015-0282(16)55704-5 · Cited by 108 · cited 1×
“The efficacy of GnRH agonist at reducing uterine volume, inducing amenorrhea, and relieving pain was demonstrated by case reports as far back as three decades ago [42,43].”
BackgroundGlobal Transcriptome Abnormalities of the Eutopic Endometrium from Women with Adenomyosis
Herndon, C. N., Aghajanova, L., Balayan, S., Erikson, D., Barragan, F., Goldfien, G., Vo, K. C., Hawkins, S., & Giudice, L. C. (2016) · Reproductive Sciences · doi:10.1177/1933719116650758 · Cited by 106 · cited 1×
“It has been demonstrated that several microRNAs are dysregulated in endometrium from adenomyosis patients, raising hopes of developing a treatment by normalizing expression of these molecules [74].”
BackgroundBADAWY, A. M., ELNASHAR, A. M., & MOSBAH, A. A. (2012) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.1111/j.1600-0412.2012.01350.x · Cited by 99 · cited 1×
“To the best of our knowledge, only one prospective study involving 32 patients has analyzed the effectiveness of letrozole compared to GnRH agonist in treating adenomyosis [67].”
BackgroundShaaban, O. M., Ali, M. K., Sabra, A. M. A., & Aal, D. E. M. A. E. (2015) · Contraception · doi:10.1016/j.contraception.2015.05.015 · Cited by 98 · cited 2×
“, a 6-month treatment with COCs did alleviate pain in adenomyosis patients, but both pain and uterine volume showed more pronounced decrease in the levonorgestrel-releasing intrauterine device (LNG-IUD)-treated group [11].”
BackgroundMethodStratton, P. (2000) · Human Reproduction · doi:10.1093/humrep/15.5.1092 · Cited by 93 · cited 1×
“It is capable of delaying ovulation and endometrial maturation by lowering serum estradiol levels [35].”
BackgroundTreatment of adenomyosis with long-term GnRH analogues: a case report.
Grow, D. R., & Filer, R. B. (1991) · PubMed · Cited by 92
Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding
Rodriguez, M. B., Lethaby, A. E., & Farquhar, C. M. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000400.pub4 · Cited by 91
Conservative surgical management for diffuse uterine adenomyosis.
Nishida, M., Takano, K., Arai, Y., Ozone, H., & Ichikawa, R. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.03.046 · Cited by 90 · cited 1×
“Uterine rupture was observed in 5 cases out of a series of 1349 patients undergoing this technique [99,100].”
BackgroundSurrey, E. S. (1999) · Fertility and Sterility · doi:10.1016/s0015-0282(98)00500-7 · Cited by 90 · cited 1×
“Addback therapy is helpful in decreasing this effect, but experts in the field have argued that long-term treatment of adenomyosis with GnRH agonist should be limited to cases not responding to other medications or where surgical intervention is not a safe option [6,47].”
BackgroundUtero‐Tubal Sperm Transport and Its Impairment in Endometriosis and Adenomyosis
KISSLER, S., ZANGOS, S., WIEGRATZ, I., KOHL, J., RODY, A., GAETJE, R., DOEBERT, N., WILDT, L., KUNZ, G., LEYENDECKER, G., et al. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1389.036 · Cited by 89 · cited 1×
“Uterine hypercontractility, a hallmark of adenomyosis, may inhibit physiological sperm transport through the female reproductive tract, thus inhibiting oocyte fertilization [81].”
BackgroundAbsence of aromatase protein and mRNA expression in endometriosis
Colette, S., Lousse, J. C., Defrere, S., Curaba, M., Heilier, J. F., Van Langendonckt, A., Mestdagt, M., Foidart, J. M., Loumaye, E., & Donnez, J. (2009) · Human Reproduction · doi:10.1093/humrep/dep199 · Cited by 88
Self-citationThe Interplay Between Prolactin and Reproductive System: Focus on Uterine Pathophysiology
Auriemma, R. S., Vecchio, G. D., Scairati, R., Pirchio, R., Liccardi, A., Verde, N., de Angelis, C., Menafra, D., Pivonello, C., Conforti, A., et al. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.594370 · Cited by 85 · cited 2×
“The association of adenomyosis and aberrant prolactin signaling is almost exclusively corroborated by findings in a mouse model, so its mechanisms of action in human adenomyosis development and symptoms are unclear [65].”
BackgroundPregnancy after medical therapy of adenomyosis with a gonadotropin-releasing hormone agonist
Hirata, J. D., Moghissi, K. S., & Ginsburg, K. A. (1993) · Fertility and Sterility · doi:10.1016/s0015-0282(16)55703-3 · Cited by 81
Origin and Pathogenic Mechanisms of Uterine Adenomyosis: What Is Known So Far
Stratopoulou, C. A., Donnez, J., & Dolmans, M. (2020) · Reproductive Sciences · doi:10.1007/s43032-020-00361-w · Cited by 79 · cited 4×
“As in endometriosis, progesterone receptors in adenomyotic uteri are either diminished or inactive, thus inhibiting the action of both local and synthetic progesterone forms [1,15,31,32].”
BackgroundInfluentialSelf-citationLive birth after treatment of severe adenomyosis with a gonadotropin-releasing hormone agonist
Silva, P. D., Perkins, H. E., & Schauberger, C. W. (1994) · Fertility and Sterility · doi:10.1016/s0015-0282(16)56471-1 · Cited by 78
Safety of medical treatments for endometriosis
Berlanda, N., Somigliana, E., Viganò, P., & Vercellini, P. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1121991 · Cited by 78 · cited 2×
“It should be noted, however, that extensive use of COCs has been linked to increased risk of thromboembolic events [13].”
BackgroundDonnez, J., Donnez, O., & Dolmans, M. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.01.035 · Cited by 73 · cited 1×
“Despite the high prevalence and severe symptoms of the disease, its pathogenesis is not yet fully understood [1,2].”
BackgroundSelf-citationGarry, R. (2004) · Human Reproduction · doi:10.1093/humrep/deh147 · Cited by 72
MR imaging of diffuse adenomyosis changes after GnRH analog therapy
Imaoka, I., Ascher, S. M., Sugimura, K., Takahashi, K., Li, H., Cuomo, F., Simon, J., & Arnold, L. L. (2002) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.10060 · Cited by 72 · cited 1×
“It was subsequently shown that a 6-month course of GnRH agonist was able to significantly reduce both uterine volume and JZ thickness in 18 adenomyosis patients, some of whom had concurrent endometriosis [44].”
BackgroundThe effect of adenomyosis on IVF after long or ultra-long GnRH agonist treatment
Hou, X., Xing, J., Shan, H., Mei, J., Sun, Y., Yan, G., Sun, H., & Wang, J. (2020) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2020.07.027 · Cited by 70 · cited 1×
“Finally, an ultra-long GnRH protocol before ovarian stimulation appears to yield better pregnancy outcomes than the corresponding long protocol [92,93].”
BackgroundLong‐term use of dienogest in the treatment of painful symptoms in adenomyosis
Osuga, Y., Watanabe, M., & Hagino, A. (2017) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.13406 · Cited by 69 · cited 1×
“Indeed, a number of clinical trials on long-term use of dienogest in women with dysmenorrhea have reported metrorrhagia as the most common side effect, occurring in almost all subjects at varying severity [17,18].”
BackgroundEfficacy of dienogest in the treatment of symptomatic adenomyosis: a pilot study
Hirata, T., Izumi, G., Takamura, M., Saito, A., Nakazawa, A., Harada, M., Hirota, Y., Koga, K., Fujii, T., & Osuga, Y. (2014) · Gynecological Endocrinology · doi:10.3109/09513590.2014.926882 · Cited by 65 · cited 1×
“However, a pilot study in 15 patients receiving dienogest for 24 weeks failed to demonstrate significant reduction in either uterine or lesion size or the width of the junctional zone, though pain relief levels were acceptable [16].”
BackgroundAndersson, J. K., Khan, Z., Weaver, A. L., Vaughan, L. E., Gemzell‐Danielsson, K., & Stewart, E. A. (2019) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.13632 · Cited by 62 · cited 2×
“, a 6-month course of vaginal bromocriptine was found to significantly reduce adenomyosis-associated pain and JZ thickness in a small number of patients [63,64].”
BackgroundHuang, B.-S., Seow, K.-M., Tsui, K.-H., Huang, C.-Y., Lu, Y.-F., & Wang, P.-H. (2012) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2012.04.008 · Cited by 61 · cited 1×
“Two studies concluded that conservative surgery combined with GnRH agonist, rather than GnRH agonist alone, is able to improve symptoms and boost reproductive potential in adenomyosis patients [90,91].”
BackgroundLan, J., Wu, Y., Wu, Z., Wu, Y., Yang, R., Liu, Y., Lin, H., Jiao, X., & Zhang, Q. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.609771 · Cited by 61 · cited 1×
“Finally, an ultra-long GnRH protocol before ovarian stimulation appears to yield better pregnancy outcomes than the corresponding long protocol [92,93].”
BackgroundAnti-platelet therapy holds promises in treating adenomyosis: experimental evidence
Zhu, B., Chen, Y., Shen, X., Liu, X., & Guo, S.-W. (2016) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-016-0198-1 · Cited by 60 · cited 2×
“One mouse model-based study suggested the potential utility of ozagrel, an antiplatelet drug, for treatment of adenomyosis, after observing enhanced platelet aggregation in mouse and human lesions [71,72].”
BackgroundSauerbrun‐Cutler, M., & Alvero, R. J. (2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2019.09.037 · Cited by 60 · cited 1×
“Despite these promising results, GnRH agonists are associated with severe hypoestrogenic side effects, especially a reduction in bone mineral density, so they cannot be used long-term, while symptoms tend to reappear upon treatment cessation [13,46].”
BackgroundManagement of Adenomyosis in Subfertile Women and Pregnancy Outcome
Al Jama, F. (2011) · Oman Medical Journal · doi:10.5001/omj.2011.43 · Cited by 59 · cited 1×
“Two studies concluded that conservative surgery combined with GnRH agonist, rather than GnRH agonist alone, is able to improve symptoms and boost reproductive potential in adenomyosis patients [90,91].”
BackgroundLong‐term use of dienogest for the treatment of primary and secondary dysmenorrhea
Osuga, Y., Hayashi, K., & Kanda, S. (2020) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.14209 · Cited by 59 · cited 1×
“Indeed, a number of clinical trials on long-term use of dienogest in women with dysmenorrhea have reported metrorrhagia as the most common side effect, occurring in almost all subjects at varying severity [17,18].”
BackgroundGonadotropin-releasing hormone antagonist (linzagolix): A new therapy for uterine adenomyosis
Donnez, O., & Donnez, J. (2020) · Fertility and Sterility · doi:10.1016/j.fertnstert.2020.04.017 · Cited by 58 · cited 3×
“demonstrated their effectiveness in lesion regression, reduction of uterine volume, and alleviation of clinical symptoms in a patient with severe adenomyosis [38] (Figure 2).”
BackgroundInfluentialSelf-citationHassanin, A. I., Youssef, A. A., Yousef, A. M., & Ali, M. K. (2021) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13600 · Cited by 52 · cited 2×
“found COCs to be effective at diminishing pain, while dienogest was superior at reducing bleeding and uterine volume, but at the cost of more side effects [12].”
BackgroundMethodUterine Adenomyosis: From Disease Pathogenesis to a New Medical Approach Using GnRH Antagonists
Donnez, J., Stratopoulou, C. A., & Dolmans, M.-M. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18199941 · Cited by 51 · cited 1×
“While not yet registered for clinical use against symptomatic adenomyosis, oral GnRH antagonists constitute an attractive option, increasingly gaining the interest of the medical community and yielding promising results in preliminary studies [49,50].”
BackgroundSelf-citationDonnez, J., & Dolmans, M.-M. (2020) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2020.05.017 · Cited by 50 · cited 2×
“This is a major advantage in the context of infertility manag ment and, as described in a r c nt review paper, would entail oocyte retrieval and vitrification followed by a 12-week course of treatment to reduce lesion size and uterine volume prior to frozen-thawed mbryo transfer [53].”
Self-citationOsuga, Y., Seki, Y., Tanimoto, M., Kusumoto, T., Kudou, K., & Terakawa, N. (2021) · BMC Women s Health · doi:10.1186/s12905-021-01393-3 · Cited by 50 · cited 2×
“Consistent with these findings, an ongoing clinical trial has reported that relugolix, another drug in the same category, can also successfully reduce endometriosis-associated pain when administered for up to 24 weeks at a dose of 40 mg [58].”
ResultDonnez, J., Dolmans, M.-M., & Fellah, L. (2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.12.018 · Cited by 49 · cited 2×
“Indeed, we have already stressed that adeno yosis and endo etriosis, particularly deep endo etriosis, frequently coexist and ay as ell share the same pathogenic origin, suggesting the potential value of extrapolating treatment results from one condition to the other [59,60].”
BackgroundSelf-citationDevelopment of uterine adenomyosis after treatment with dopamine antagonists in mice
Singtripop, T., Mori, T., Kyun, P. M., Sakamoto, S., & Kawashima, S. (1991) · Life Sciences · doi:10.1016/0024-3205(91)90004-u · Cited by 48 · cited 1×
“Its use is based on the observation that prolactin is aberrantly expressed and may induce an adenomyosis-like phenotype in mouse models [61,62].”
BackgroundEndometrial changes during ulipristal acetate use: A systematic review
de Milliano, I., Hattum, D. V., Ket, J. C. F., Huirne, J. A. F., & Hehenkamp, W. J. K. (2017) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2017.04.042 · Cited by 47 · cited 1×
“Ulipristal acetate (UPA) is a selective progesterone receptor modulator currently registered for specific clinical indications: emergency contraception and long-term management of symptomatic uterine fibroids or prior to myoma surgery [33,34].”
BackgroundHu, H., Li, H., & He, Y. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.5013 · Cited by 45
Exploring the challenges for a new classification of adenomyosis
Habiba, M. A., Gordts, S., Bazot, M., Brosens, I. A., & Benagiano, G. (2020) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2020.01.017 · Cited by 45
Kimura, F., Takahashi, K., Takebayashi, K., Fujiwara, M., Kita, N., Noda, Y., & Harada, N. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.09.010 · Cited by 41 · cited 1×
“In one case report, concomitant administration of an oral aromatase inhibitor (anastrozole) and a GnRH agonist (goserelin acetate) was successful in reducing uterine volume and inhibiting bleeding in a patient with endometriosis and severe adenomyosis, who was resistant to progestin [66].”
BackgroundUlipristal Acetate Improves Clinical Symptoms in Women with Adenomyosis and Uterine Myomas
Gràcia, M., Alcalà, M., Ferreri, J., Rius, M., Ros, C., Saco, M. A., Martínez‐Zamora, M. Á., & Carmona, F. (2018) · Journal of Minimally Invasive Gynecology · doi:10.1016/j.jmig.2018.04.002 · Cited by 34 · cited 1×
“Two recent studies reported a diminution in blood loss after a 12-week treatment with UPA in 30 patients with adenomyosis and 41 patients with concurrent adenomyosis and leiomyoma [36,37].”
BackgroundMatsubara, S., Kawaguchi, R., Akinishi, M., Nagayasu, M., Iwai, K., Niiro, E., Yamada, Y., Tanase, Y., & Kobayashi, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-54096-z · Cited by 34 · cited 1×
“[20]) may be more prone to developing serious menorrhagia upon dienogest administration than other disease subtypes [21].”
BackgroundLong‐term durability of uterine artery embolisation for treatment of symptomatic adenomyosis
Ma, J., Brown, B., & Liang, E. Y. (2021) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.13304 · Cited by 34 · cited 2×
“During this angiographic procedure, an embolic agent is injected into the uterine arteries to induce ischaemic infarction of adenomyotic foci [101,102].”
BackgroundMethodUlipristal acetate use in adenomyosis: A randomized controlled trial
Capmas, P., Brun, J.-L., Legendre, G., Koskas, M., Merviel, P., & Fernandez, H. (2020) · Journal of Gynecology Obstetrics and Human Reproduction · doi:10.1016/j.jogoh.2020.101978 · Cited by 31 · cited 1×
“Two recent studies reported a diminution in blood loss after a 12-week treatment with UPA in 30 patients with adenomyosis and 41 patients with concurrent adenomyosis and leiomyoma [36,37].”
BackgroundHuang, J., Duan, H., Wang, S., Wang, Y., & Lv, C.-X. (2021) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-021-00753-w · Cited by 30
Identifying Common Pathogenic Features in Deep Endometriotic Nodules and Uterine Adenomyosis
Stratopoulou, C. A., Camboni, A., Donnez, J., & Dolmans, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194585 · Cited by 30 · cited 3×
“No data are yet available on the possible effect of ozagrel or other anti-platelet agents on human adenomyosis, while the actual role of platelet aggregation in its pathogenesis remains contentious [60,73].”
BackgroundSelf-citationAdenomyosis; its conservative surgical treatment (hysteroplasty) in young women.
Ll, H. (1952) · PubMed · Cited by 29
Conway, F., Morosetti, G., Camilli, S., Martire, F. G., Sorrenti, G., Piccione, E., Zupi, E., & Exacoustós, C. (2018) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1505846 · Cited by 29 · cited 3×
“demonstrated exacerbation of ultrasound characteristics of adenomyosis in women inappropriately treated with UPA for leiomyomas, observing enlarged intramyometrial cysts and enhanced vascularization [39].”
BackgroundResultWang, Y., Duan, H., Wang, S., Quan, Y., Huang, J., & Guo, Z. (2021) · Reproductive Sciences · doi:10.1007/s43032-020-00444-8 · Cited by 29
Donnez, J., Donnez, O., Tourniaire, J., Brethous, M., Bestel, E., Garner, E. I. O., Charpentier, S., Humberstone, A., & Loumaye, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245794 · Cited by 29
Self-citationMorelli, M., Rocca, M. L., Venturella, R., Mocciaro, R., & Zullo, F. (2013) · Gynecological Endocrinology · doi:10.3109/09513590.2012.743017 · Cited by 28 · cited 1×
“Its effect on chronic pelvic pain symptoms also appears considerable, curbing pain medication use and curtailing lost work productivity [45].”
BackgroundNiu, X., Luo, Q., Wang, C., Zhu, L. J., & Huang, L. (2021) · Medicine · doi:10.1097/md.0000000000024597 · Cited by 27
Donnez, J., Donnez, O., Brethous, M., Bestel, E., Garner, E. I. O., Charpentier, S., Humberstone, A., & Loumaye, E. (2021) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2021.09.019 · Cited by 27 · cited 3×
“Future studies will determine the advantages of continuing the intake of linzagolix 100 mg daily after week 24 to avoid regrowth of the uterus [51].”
BackgroundResultInfluentialSelf-citationSong, S. Y., Lee, S. Y., Kim, H. Y., Park, D. B., Kim, D. E., Lee, K. H., Lee, S., Yang, J. B., & Yoo, H. J. (2020) · Medicine · doi:10.1097/md.0000000000020421 · Cited by 26 · cited 1×
“A more recent retrospective study suggested that the beneficial impact of LNG-IUDs on heavy bleeding and dysmenorrhea, but not uterine volume reduction, may last up to six years post-insertion [30].”
BackgroundIncreased expression of prolactin receptor mRNA in adenomyotic uterus in mice
Yamashita, M., Matsuda, M., & Mori, T. (1997) · Life Sciences · doi:10.1016/s0024-3205(96)00649-2 · Cited by 25 · cited 1×
“Its use is based on the observation that prolactin is aberrantly expressed and may induce an adenomyosis-like phenotype in mouse models [61,62].”
BackgroundEkin, M., Cengiz, H., Ayağ, M. E., Kaya, C., Yaşar, L., & Savan, K. (2013) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2013.07.019 · Cited by 25
Xie, M., Yu, H., Zhang, X., Wang, W., & Ren, Y. (2019) · Journal of Gynecology Obstetrics and Human Reproduction · doi:10.1016/j.jogoh.2019.05.003 · Cited by 24 · cited 1×
“In fact, according to a study of 45 subjects, triptorelin with add-back therapy may be beneficial to infertile patients irrespective of IVF, by reducing uterine size and enhancing elasticity, hence facilitating spontaneous pregnancy [85].”
BackgroundAndersson, J. K., Mucelli, R. P., Epstein, E., Stewart, E. A., & Gemzell‐Danielsson, K. (2020) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2020.08.040 · Cited by 23 · cited 1×
“, a 6-month course of vaginal bromocriptine was found to significantly reduce adenomyosis-associated pain and JZ thickness in a small number of patients [63,64].”
BackgroundWu, J., Huang, Y., Chen, L., Hu, J., & Zou, Y. (2018) · Medical Science Monitor · doi:10.12659/msm.908979 · Cited by 20 · cited 1×
“Decreased uterine volume, an important parameter linked to menorrhagia, may or may not be achieved in adenomyosis patients treated with etonogestrel, depending on the study [23,24].”
BackgroundAbrão, M. S., Surrey, E. S., Gordon, K., Snabes, M. C., Wang, H., Ijacu, H., & Taylor, H. S. (2021) · BMC Women s Health · doi:10.1186/s12905-021-01385-3 · Cited by 19 · cited 2×
“Moreover, although one trial showed loss of bone mineral density at higher doses, add-back therapy could be avoided with the 75 mg dose, while still maintaining the treatment’s beneficial effects [55].”
BackgroundInvestigation of the role of platelets in the aetiopathogenesis of adenomyosis
Mosele, S., Stratopoulou, C. A., Camboni, A., Donnez, J., & Dolmans, M. (2021) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2021.01.009 · Cited by 17 · cited 1×
“No data are yet available on the possible effect of ozagrel or other anti-platelet agents on human adenomyosis, while the actual role of platelet aggregation in its pathogenesis remains contentious [60,73].”
BackgroundSelf-citationColette, S., & Donnez, J. (2009) · New England Journal of Medicine · doi:10.1056/nejmc090328 · Cited by 16
Self-citationBorini, A., & Coticchio, G. (2020) · Fertility and Sterility · doi:10.1016/j.fertnstert.2020.06.003 · Cited by 15
Calderon, L., Netter, A., Grob, A., Mancini, J., Siles, P., Vidal, V., & Agostini, A. (2020) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2020.11.012 · Cited by 11 · cited 1×
“observed progression of adenomyosis by MRI as early as three months after UPA treatment initiation in patients with concurrent leiomyomas [40].”
BackgroundThe Endometrial Approach in Contraception
Lévy, D., Christin‐Maître, S., Leroy, I., Bergeron, C., GARCIA, E., FREITAS, S., Bennink, H. J. T. C., & Bouchard, P. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb48524.x · Cited by 9 · cited 2×
“Progestins exert a broad range of contraceptive effects, including on the endometrium, which they render non-receptive to embryos [14].”
BackgroundResultNie, L., Zou, H., Ma, X., Cheng, L., Jiao, J., Wang, F., Liang, W., & Zhang, P. (2021) · Gynecological Endocrinology · doi:10.1080/09513590.2021.1922886 · Cited by 9 · cited 1×
“Decreased uterine volume, an important parameter linked to menorrhagia, may or may not be achieved in adenomyosis patients treated with etonogestrel, depending on the study [23,24].”
BackgroundYu, K., Cui, S., & Xue, T. (2021) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.14665 · Cited by 7
Agrawala, S., Patil, J., Campbell, S. B., & Woodard, T. L. (2021) · Fertility Research and Practice · doi:10.1186/s40738-021-00097-4 · Cited by 4 · cited 1×
“One of these women later presented with severe pregnancy complications due to insufficiently decidualized endometrium, but it was not clear whether this event was related to the effect of GnRH agonist [88].”
BackgroundDonnez, O., & Donnez, J. (2021) · Human Reproduction · doi:10.1093/humrep/deab130.298 · Cited by 3
Self-citation
Research works printed but not linked: 3
- Fujishita, 2010, Shikyusenkinsho to shikyu no onzon-chiryo. Uterine adenomyosis and uterine preservation treatment, J. Obstet. Gynecol. Pract., 59, 769
- Osada, 2017, Shikyukin furappuho niyoru shikyu-senkinsho tekishutsujutsu: Rinshoteki choki-yogo oyobi shikyuharetsu-yobokoka no kento. Adenomyomectomy by uterine muscle flap method: Clinical outcome and investigation of the preventive effect on uterine rupture, Obstet. Gynecol., 84, 1303
- Nishida, 2016, Shikyusenkinsho-kakushutsujutsu-go ninshin-ji no shikyuharetsu-yobo ni tsuite (Prevention of uterine rupture during pregnancy after adenomyomectomy), Obstet. Gynecol. Surg., 27, 69
Cited by
Cracking the enigma of adenomyosis: an update on its pathogenesis and pathophysiology
Guo, S. (2022) · Reproduction · doi:10.1530/rep-22-0224 · Cited by 100
Endometriosis and adenomyosis: Similarities and differences
Donnez, J., Stratopoulou, C. A., & Dolmans, M.-M. (2024) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2023.102432 · Cited by 57
Self-citationAdenomyosis and Adolescence: A Challenging Diagnosis and Complex Management
Martire, F. G., d’Abate, C., Schettini, G., Cimino, G., Ginetti, A., Colombi, I., Cannoni, A., Centini, G., Zupi, E., & Lazzeri, L. (2024) · Diagnostics · doi:10.3390/diagnostics14212344 · Cited by 46
“Differentiating these from benign conditions like adenomyosis requires careful imaging and, in some cases, histopathological evaluation [37,78].”
BackgroundSztachelska, M., Ponikwicka‐Tyszko, D., Martínez-Rodrigo, L., Bernaczyk, P., Palak, E., Półchłopek, W., Bielawski, T., & Wołczyński, S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154407 · Cited by 41
Stratopoulou, C. A., Cussac, S., d'Argent, M., Donnez, J., & Dolmans, M. (2023) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2023.01.001 · Cited by 38
Self-citation
Metadata
- Authors
- Stratopoulou, C. A., Donnez, J., & Dolmans, M.-M.
- Affiliations
- UCLouvain (BE)
- Cliniques Universitaires Saint-Luc (BE)
- Corresponding author
- Dolmans, Marie-Madeleine
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2021-10-22
- Volume
- 10
- Issue
- 21
- Pages
- 4878
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC8584979
- OpenAlex
- W3210890914
- Cited by
- 62
- References
- 103
- Citations by year
- 2026: 9 · 2025: 12 · 2024: 13 · 2023: 18 · 2022: 9 · 2021: 1
- FWCI
- 1.68
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DIAL (Catholic University of Leuven) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Fonds National de la Recherche Scientifique de Belgique (5/4/150/5)
- PregLem via the Fondation Saint-Luc (N/A)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Uterine Myomas and Treatments
- Health Sciences › Medicine › Obstetrics and Gynecology › Gynecological conditions and treatments
- Keywords
- uterine adenomyosis, conservative treatment, medical management, surgical management, fertility preservation, hysterectomy, menorrhagia, pelvic pain, infertility, nulliparous women, uterine rupture, GnRH antagonist, off-label drug use
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.